Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC lowered its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 8.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,763 shares of the biopharmaceutical company’s stock after selling 161 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Alnylam Pharmaceuticals were worth $415,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently added to or reduced their stakes in ALNY. Allworth Financial LP raised its stake in shares of Alnylam Pharmaceuticals by 6.8% during the 4th quarter. Allworth Financial LP now owns 597 shares of the biopharmaceutical company’s stock worth $140,000 after buying an additional 38 shares during the last quarter. Huntington National Bank increased its holdings in Alnylam Pharmaceuticals by 91.8% during the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 45 shares in the last quarter. IFP Advisors Inc raised its position in Alnylam Pharmaceuticals by 24.2% during the fourth quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company’s stock worth $57,000 after acquiring an additional 47 shares during the last quarter. Nwam LLC raised its holdings in shares of Alnylam Pharmaceuticals by 5.8% in the fourth quarter. Nwam LLC now owns 906 shares of the biopharmaceutical company’s stock worth $213,000 after acquiring an additional 50 shares during the last quarter. Finally, SYM FINANCIAL Corp boosted its stake in shares of Alnylam Pharmaceuticals by 6.2% during the 3rd quarter. SYM FINANCIAL Corp now owns 947 shares of the biopharmaceutical company’s stock worth $260,000 after purchasing an additional 55 shares during the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CMO Pushkal Garg sold 52,592 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, January 27th. The stock was sold at an average price of $285.00, for a total value of $14,988,720.00. Following the transaction, the chief marketing officer now directly owns 11,989 shares in the company, valued at $3,416,865. The trade was a 81.44 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total transaction of $362,246.40. Following the completion of the transaction, the executive vice president now owns 12,881 shares of the company’s stock, valued at approximately $3,240,344.36. The trade was a 10.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 72,986 shares of company stock valued at $20,397,849 over the last three months. Company insiders own 1.50% of the company’s stock.

Analyst Ratings Changes

ALNY has been the topic of a number of research analyst reports. Chardan Capital reissued a “buy” rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. Sanford C. Bernstein dropped their price objective on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a research report on Tuesday, January 7th. Canaccord Genuity Group lifted their target price on shares of Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the company a “buy” rating in a report on Tuesday, February 18th. StockNews.com downgraded Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 9th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $310.00 price target on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have issued a buy rating to the company. According to data from MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $304.26.

Alnylam Pharmaceuticals Trading Down 1.5 %

Alnylam Pharmaceuticals stock opened at $244.52 on Monday. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $304.39. The firm has a market capitalization of $31.65 billion, a price-to-earnings ratio of -112.68 and a beta of 0.39. The firm has a 50-day moving average price of $254.70 and a two-hundred day moving average price of $261.25. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.